A Randomized, Double-blinded, Open Label Study of the Efficacy and Safety of Cefcapene Pivoxil and Amoxicillin∙Clavulanate in Acute Presumed Bacterial Rhinosinusitis
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives. Currently established first line therapy of acute (presumed bacterial) rhinosinusitis (ARS) consists of 10 to 14 days of oral amoxicillin or cephalosporins. This study compared the clinical efficacy and tolerance of cefcapene pivoxil (CP) and amoxicillin-clavulanate (AMC) in patients with ARS. Methods. A randomized, open labeled, double-blinded trial of ARS patients over 15 years of age was performed. Patients diagnosed with ARS received paranasal sinus X-rays and nasal endoscopies and 2 weeks of either CP (150 mg, 3 times/ day) or AMC (625 mg, amoxicillin 500 mg, 3 times/day). All patients revisited the clinic on days 7, 14, and 28 for evaluation of changes in symptoms, endoscopy, and monitoring of any adverse reactions. Demographics, clinical characteristics and drug efficacy were also compared between the two groups. Results. Among the 60 initially enrolled patients (CP 30, AMC 30), 5 patients in the CP group and 6 in the AMC group were excluded due to poor compliance. There were no significant differences in demographic data including age, sex, initial signs and symptoms, endoscopic and X-ray findings between the two groups. Rates of improvement after 2 weeks were 96% and 95.8% in the CP and AMC group, respectively. Sinus symptoms were changed significantly after 2 and 4 weeks, however, there was no difference between groups (P=0.41). The most common adverse reaction was gastrointestinal complication, diarrhea occurred in 1 patient in the CP group and 6 in the AMC group (P=0.04). Conclusion. CP and AMC were both effective in treating ARS. The difference of treatment outcome was not found between the two groups, however, gastrointestinal complications were less prevalent in the CP group
Abstract
Objectives. Currently established first line therapy of acute (presumed bacterial) rhinosinusitis (ARS) consists of 10 to 14 days of oral amoxicillin or cephalosporins. This study compared the clinical efficacy and tolerance of cefcapene pivoxil (CP) and amoxicillin-clavulanate (AMC) in patients with ARS. Methods. A randomized, open labeled, double-blinded trial of ARS patients over 15 years of age was performed. Patients diagnosed with ARS received paranasal sinus X-rays and nasal endoscopies and 2 weeks of either CP (150 mg, 3 times/ day) or AMC (625 mg, amoxicillin 500 mg, 3 times/day). All patients revisited the clinic on days 7, 14, and 28 for evaluation of changes in symptoms, endoscopy, and monitoring of any adverse reactions. Demographics, clinical characteristics and drug efficacy were also compared between the two groups. Results. Among the 60 initially enrolled patients (CP 30, AMC 30), 5 patients in the CP group and 6 in the AMC group were excluded due to poor compliance. There were no significant differences in demographic data including age, sex, initial signs and symptoms, endoscopic and X-ray findings between the two groups. Rates of improvement after 2 weeks were 96% and 95.8% in the CP and AMC group, respectively. Sinus symptoms were changed significantly after 2 and 4 weeks, however, there was no difference between groups (P=0.41). The most common adverse reaction was gastrointestinal complication, diarrhea occurred in 1 patient in the CP group and 6 in the AMC group (P=0.04). Conclusion. CP and AMC were both effective in treating ARS. The difference of treatment outcome was not found between the two groups, however, gastrointestinal complications were less prevalent in the CP group
참고문헌 (14)
- Anon JB, "Antimicrobial treatment guidelines for acute bacterial rhinosinusitis", Otolaryngol Head Neck Surg, 130(1), pp.1~45 (2004)
- Wald ER, "Microbiology of acute and chronic sinusitis in children", J Allergy Clin Immunol, 90(3), pp.452~456 (1992)
- Sakata H, "Comparative study of 5-day cefcapene-pivoxil and 10-day amoxicillin or cefcapene-pivoxil for treatment of group A streptococcal pharyngitis in children", J Infect Chemother, 14(3), pp.208~212 (2008)
- Lanza DC, "Adult rhinosinusitis defined", Otolaryngol Head Neck Surg, 117(3), pp.S1~7 (1997)
- Anon JB, "Efficacy", safety of amoxicillin, Am J Otolaryngol, pp.2006, 27(4)[DOI]
- Tantimongkolsuk C, "Pediatric sinusitis:symptom profiles with associated atopic conditions", J Med Assoc Thai, 88(Suppl 8), pp.S149~155 (2005)
- Young J, "Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data", Lancet, 371(9616), pp.908~914 (2008)
- Rosenfeld RM, "Clinical practice guideline: adult sinusitis", Otolaryngol Head Neck Surg, 137(3 Suppl), pp.S1~31 (2007)
- Garbutt JM, "A randomized, placebo-controlled trial of antimicrobial treatment for children with clinically diagnosed acute sinusitis", Pediatrics, 107(4), pp.619~625 (2001)
- Bottenfield GW, "Safety and tolerability of a new formulation (90 mg", kg, clavulanate (Augmentin) in the empiric treatment of pediatric acute otitis media caused by drug-resistant Streptococcus pneumoniae, pp.Pediatr Infect Dis J, 1998[DOI]
- Poachanukoon O, "Efficacy of cefditoren pivoxil and amoxicillin", clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial, 2008, pp.30(10), 1870~1879
- Kafetzis DA, "Multi-investigator evaluation of the efficacy and safety of cefprozil, amoxicillin-clavulanate, cefixime and cefaclor in the treatment of acute otitis media", Eur J Clin Microbiol Infect Dis, 13(10), pp.857~865 (1994)
- Henry DC, "Cefdinir versus levofloxacin in patients with acute rhinosinusitis of presumed bacterial etiology: a multicenter, randomized, double-blind study", Clin Ther, 26(12), pp.2026~2033 (2004)
- Benninger MS, "Endoscopically directed middle meatal cultures versus maxillary sinus taps in acute bacterial maxillary rhinosinusitis: a meta-analysis", Otolaryngol Head Neck Surg, 134(1), pp.3~9 (2006)